A putative therapeutic target in neurofibromatosis type 1: P21359

Ablatotech Signals reports today on a putative therapeutic target — P21359 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in neurofibromatosis type 1.

Background

The putative target P21359 has been identified as a candidate protein associated with neurofibromatosis type 1 (NF1), a rare genetic disorder characterized by the development of multiple benign tumors called neurofibromas, as well as other neurological and skin manifestations. This candidate has emerged from expression-profiling studies, suggesting a potential involvement in the pathophysiology of NF1. However, it is important to note that there are currently no registered Phase 1 or higher clinical programs targeting this protein, indicating a significant opportunity for further research and therapeutic exploration.

Data-mining rationale

The identification of P21359 as a putative target was accomplished by cross-referencing UniProt's reviewed human entries related to "neurofibromatosis type 1" against 17 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This systematic analysis enabled the identification of relevant gene expression patterns that may contribute to our understanding of NF1, positioning P21359 as a noteworthy candidate for further investigation.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The absence of appropriate multiple-testing correction in earlier studies may have resulted in the oversight of significant expression changes associated with P21359. Therefore, a re-analysis of these datasets using contemporary statistical techniques could provide new insights into the potential role of this candidate in neurofibromatosis type 1.

Reasoning for further validation

To substantiate the potential relevance of P21359 in neurofibromatosis type 1, the following experimental approaches are suggested: 1. Re-analyze the matched GEO datasets using limma with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes, including P21359, through quantitative PCR (qPCR) in an independent cohort to confirm expression patterns. 3. Investigate the tissue specificity of P21359 by utilizing resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its expression across various tissues. 4. Employ pathway analysis tools like STRING and OmniPath to explore the biological pathways in which P21359 may be involved, providing context for its potential role in neurofibromatosis type 1. 5. If validation is achieved, assess the druggability of P21359 using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References